CAIX Score Quantifies Tumor Expression for Targeted Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating cancer lack a standardized approach to quantify CAIX expression and predict the effectiveness of CAIX-targeting compounds, which are crucial for personalized cancer therapy.
Innovation Solution
A novel CAIX score is introduced, calculated based on the combination of tumor cell extent and staining intensity, allowing for the characterization of cancer and determining the suitability of CAIX-targeting compounds for treatment by quantifying CAIX expression in tumor samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If CAIX expression is quantified using traditional immunohistochemical staining methods, then cancer diagnosis and treatment information can be obtained, but the measurement lacks standardization and precision for predicting treatment effectiveness
Solution Approach 1:
The patent transforms the qualitative immunohistochemical staining results into a quantitative standardized scoring system. The CAIX score is calculated by multiplying the staining intensity (0-3 scale) by the percentage of positive tumor cells (0-100 scale), creating a standardized numerical parameter that enables precise measurement and comparison of CAIX expression levels across different samples and predicts treatment effectiveness with CAIX-targeting compounds.
2Reliability
If a standardized CAIX score system is implemented to predict treatment outcomes, then treatment effectiveness can be predicted, but the diagnostic process becomes more complex
Solution Approach 1:
The patent establishes a standardized CAIX score parameter that combines staining intensity and cell percentage into a single reliable predictive metric. This standardized parameter enables consistent treatment outcome predictions across different clinical settings while providing clear guidance for selecting patients who will benefit from CAIX-targeting compound therapy.
Solution Approach 2:
The CAIX score acts as an intermediary parameter that bridges the gap between immunohistochemical staining results and treatment effectiveness prediction. By introducing this standardized scoring system as an intermediate step, the patent translates complex staining patterns into a simple, interpretable metric that reliably predicts which patients will respond to CAIX-targeting therapy.
3Stability of the object's composition
If immunohistochemical staining is performed to detect CAIX expression, then cancer characterization is possible, but the method lacks standardization for consistent results across different samples
Solution Approach 1:
The patent introduces a standardized scoring parameter that transforms variable qualitative staining observations into consistent quantitative measurements. The CAIX score system standardizes the evaluation process by defining specific intensity levels (0-3) and requiring calculation based on the percentage of positive cells, ensuring that results are stable and comparable across different samples, laboratories, and observers.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CAIX score effectively predicts treatment outcomes, particularly for renal clear cell carcinoma, enabling targeted therapy with compounds like anti-G250 antibodies, showing significant treatment effects for patients with scores ≥2.6, thereby improving cancer treatment efficacy.
Implementation Method 1
The monoclonal antibody G250 recognizes an antigen preferably expressed on membranes of renal cell carcinoma cells (RCC), but not expressed in normal proximal tubular epithelium. The G250 antibody binds to the antigen G250, which is also called MN antigen (cf., for example, WO 93/18152) or CAIX (carbonic anhydrase IX).
Implementation Method 2
The transmembrane protein carbonic anhydrase IX (CAIX) is a member of the large family of carbonic anhydrase enzymes which share the ability to catalyze the reversible hydration of carbon dioxide to carbonic acid, leading to a decrease in pH
Data Source
AI summary
The present invention relates to a carbonic anhydrase IX targeting compound for the use in the treatment of cancer, wherein the use comprises quantifying CAIX expression as well as the determination of a CAIX score based on the CAIX expression. The present invention relates further to a method for diagnosing, predicting and/or classifying a cancer disease comprising quantifying CAIX expression, and the determination of a CAIX score.